The retrieved chunks don't contain named recommendations for specific UK healthtech VCs. They discuss the VC model's fit within healthtech generally—the mismatch between venture capital speed and healthtech's regulatory complexity [#382][Ep 55]—and mention Oxford Sciences Innovation [#137], but don't evaluate UK firms or their track records.
A sharper question would be: "Which VCs have backed the most successful UK healthtech exits?" or "What do UK healthtech VCs look for in a founding team?"
Search 450+ episodes and 42,000 chunks of healthtech conversation.